Cash Flow Statement
Growth Metrics

Xtant Medical Holdings (XTNT) Cost of Revenue (2016 - 2025)

Xtant Medical Holdings has reported Cost of Revenue over the past 16 years, most recently at $11.7 million for Q3 2025.

  • Quarterly Cost of Revenue fell 1.21% to $11.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $46.1 million through Sep 2025, down 2.41% year-over-year, with the annual reading at $49.1 million for FY2024, 27.61% up from the prior year.
  • Cost of Revenue was $11.7 million for Q3 2025 at Xtant Medical Holdings, up from $11.6 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $13.2 million in Q2 2024 and troughed at $4.5 million in Q4 2021.
  • The 5-year median for Cost of Revenue is $7.8 million (2023), against an average of $8.7 million.
  • Year-over-year, Cost of Revenue surged 89.88% in 2023 and then fell 11.86% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $4.5 million in 2021, then soared by 53.83% to $7.0 million in 2022, then soared by 66.34% to $11.6 million in 2023, then fell by 0.54% to $11.5 million in 2024, then grew by 1.95% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Cost of Revenue are $11.7 million (Q3 2025), $11.6 million (Q2 2025), and $11.2 million (Q1 2025).